The new drugs show promise in fighting Parkinson’s disease, minimizing unnecessary side effects.
Tabapadon, a once-daily pill, was found to relieve symptoms, including stiffness, coordination, trembling and movement. This is because patients who took at least 400 mg of levodopa a day and were experiencing “movement fluctuations,” drugs have been exhausted, symptoms resurrected, and studies say symptoms have returned.
Until now, levodopa has been the standard first-line treatment for patients with Parkinson’s disease.
The Parkinson’s disease incident could double globally by 2050, research reveals
Levodopa, which is converted to dopamine in the brain and targets D2/D3/D4 dopamine receptors, is associated with side effects such as sleep disorders, hallucinations, impulse control behavior disorders, weight gain, swelling of the legs, and changes in blood pressure, according to researchers.
The new drugs show promise in fighting Parkinson’s disease, minimizing unnecessary side effects. (istock)
This study found that tabapadon, which mimics dopamine and functions by targeting the D1/D5 receptor, has the same benefits as levodopa without side effects, according to Hubert H. Fernandez, MD, lead research author and director at the Cleveland Clinical Neurological Repair Center.
Dance relieves depression symptoms in Parkinson’s patients, new research suggests
“It offers patients another option to mitigate the movement variability commonly experienced with levodopa (the best drug ever had in Parkinson’s disease), at a moderate to advanced stage of the disorder,” Fernandez told Fox News Digital.
“This global multicenter pivotal trial showed that patients placed in Tabapadon were “on-time” and “on-time” and “on-hours” compared to patients who received a placebo, and that the drug was well tolerated by the patients. ”
Tavapadon is a tablet once a day, while levodopa, the current first-line drug, requires three tablets every day. (istock)
In this study, the researchers measured patients’ impulse control behavioral disorders, excessive daytime drowsiness, changes in blood pressure, and weight, and found that side effects associated with tabapadon were not different from those who received a placebo.
“Of course, this is a short-term study and we need to wait for our long-term research to truly be certain that our preliminary observations remain true,” Fernandez pointed out. “Nottheless, we are highly encouraged.”
“Regardless of when it was used, whether it was initially adjuvant therapy with levodopa, I think it’s a benefit overall.”
Researchers presented the results of the Tempo 3 exam at the American Society of Neurology (AAN) in San Diego earlier this month.
For those recently diagnosed and with fewer severe motor symptoms, Fernandez suggested that once-daily tabapadon doses could potentially replace three times the daily dose of levodopa.
“It offers patients another option to mitigate the movement variability commonly experienced with levodopa (the best drug ever had in Parkinson’s disease), at moderate to advanced stages of the disorder,” the researchers said. (istock)
“If levodopa is required at some point, a lower dose and less frequent will be required, reducing the likelihood that it will develop motor fluctuations and dyskinesia and other side effects,” he said in a press release.
For people with more advanced Parkinson’s disease, tabapadon may be paired with levodopa.
In Brett Fabre’s Parkinson’s diagnosis, neurologists discuss how concussions affect risks
“Regardless of when it’s being used, whether it’s adjuvant therapy with levodopa at first, I think it’s a benefit overall,” Fernandez added.
Recent studies have predicted that Parkinson’s cases will surge by 2050, affecting up to 25 million people worldwide.
The biggest increase will affect people over 80 years old, and cases in that age group are projected to increase by 196% by 2050, they noted.
Among people over the age of 80, Parkinson’s disease cases are projected to increase by 196% by 2050. (istock)
With the long-term trial results pending, Abbvie, the maker of Tabapadon, will immediately submit an application to the Food and Drug Administration for approval of the drug.
“The FDA then reviews the application. From there you can either approve its use, ask questions that may not be clear, or request an extension to validate another investigation or some results,” Fernandez said.
Click here to get the Fox News app
“This new generation of dopamine agonists hopes that dopamine receptor stimulation will be more selective and will only be given once a day.
Click here to sign up for our health newsletter
Dr. Mary Ampicone, medical director at MS Center at Holy Name Medical Center in Teenick, New Jersey, was not involved in the study, but called the results “a very interesting and encouraging new tools to improve the quality of life for people with Parkinson’s disease.”
Recent studies have predicted that Parkinson’s cases will surge by 2050, affecting up to 25 million people worldwide.
“One of the major limitations of long-term use of dopamine is the wear phenomenon and the need to administer it more frequently,” Picone told Fox News Digital.
“The use of dopamine agonists helps to extend the long-term benefits of dopamine. A lower dopamine profit can lead to “freezing,” or episodes where patients increase stiffness and difficult to move. ”
For health articles, please visit www.foxnews.com/health
“This new treatment targets different receptors and “enables at ‘more’ times” but lacks involuntary dyskinesia (uncontrolled movement) that can interfere with function. ”
